Treatment for Non-Falciparum Malaria
Chloroquine is the first-line treatment for uncomplicated P. vivax, P. ovale, P. malariae, and P. knowlesi malaria, followed by primaquine (or tafenoquine) for P. vivax and P. ovale to prevent relapse. 1
Treatment Algorithm by Species and Severity
P. vivax and P. ovale (Uncomplicated)
First-line: Chloroquine
- Dosing: 1000 mg salt initially, then 500 mg salt at 6,24, and 48 hours (total 25 mg base/kg over 3 days) 1
- Alternative formulations: Chloroquine sulphate (600 mg base, then 300 mg base at same intervals) or Hydroxychloroquine (800 mg salt, then 400 mg salt) 1
Second-line: Artemisinin-based combination therapy (ACT)
- Use dihydroartemisinin-piperaquine (DHA-PPQ) or artemether-lumefantrine (AL) 1
- Critical indication: Mandatory for chloroquine-resistant areas (Papua New Guinea, Indonesia, Sabah) where failure rates exceed 10% 1
- Meta-analysis shows DHA-PPQ superior to chloroquine (HR 2.33) and AL (HR 2.07) for preventing recurrence 1
Anti-relapse therapy (ESSENTIAL for P. vivax and P. ovale):
Primaquine:
- Standard dose: 30 mg base daily for 14 days 1
- 80% risk reduction in relapse 1
- MANDATORY G6PD testing before administration 1
- For intermediate G6PD deficiency (30-70% activity, non-Mediterranean variant): 45 mg weekly for 8 weeks with close monitoring 1
- Contraindicated in pregnancy and breastfeeding 1
Tafenoquine:
- Single 300 mg dose 1
- Requires quantitative G6PD testing (do not use if <70% activity) 1
- Only available in United States and Australia 1
- Contraindicated in pregnancy 1
P. malariae and P. knowlesi (Uncomplicated)
First-line: Chloroquine
- Same dosing as P. vivax: 1000 mg salt initially, then 500 mg salt at 6,24, and 48 hours 1
Second-line: ACT
- DHA-PPQ or AL 1
- Important for P. knowlesi: ACT provides faster parasite clearance and lower anemia rates compared to chloroquine 2
Severe Malaria (All Species)
First-line: Intravenous artesunate
- Dosing: 2.4 mg/kg IV at 0,12, and 24 hours, then 2.4 mg/kg daily 1
- Continue for 7 days if unable to take oral medication or parasitemia >1% 1
- Switch to oral ACT once able to take oral medication and parasitemia <1% (complete full course) 1
- Demonstrated faster parasite clearance and shorter ICU stay versus quinine 1
Second-line: Quinine dihydrochloride
- Loading dose: 20 mg salt/kg over 4 hours
- Maintenance: 10 mg/kg over 4 hours every 8 hours (starting 8 hours after loading dose initiation) 1
- Switch to oral therapy after minimum 48 hours IV treatment 1
Critical Caveats and Common Pitfalls
G6PD Testing:
- Never skip this step before primaquine or tafenoquine administration 1
- Mediterranean variant (B-) has very high risk of severe hemolysis; African variant (A-) has milder deficiency 1
- Hemolysis risk is the main limiting factor for 8-aminoquinoline use 1
Geographic Resistance Patterns:
- Papua New Guinea, Indonesia, and Sabah: Chloroquine resistance documented—use ACT instead 1
- Always obtain detailed travel history to guide drug selection
Pregnancy Considerations:
- Chloroquine safe in all trimesters 1
- Quinine safe in all trimesters 1
- Primaquine and tafenoquine absolutely contraindicated 1
- AL now endorsed by WHO and CDC for all trimesters 1
Post-Artesunate Delayed Hemolysis (PADH):
- Monitor for hemolysis up to day 14 after treatment 1
- Recent studies show 37.4% prevalence using strict definitions 1
- Requires structured clinical follow-up
Relapse Prevention:
- Failure to provide anti-relapse therapy for P. vivax/P. ovale results in 9.3% and 4.1% relapse rates respectively 1
- This is a critical quality-of-life issue—relapses cause repeated illness and treatment burden
Drug Interactions: